Vallon Pharmaceuticals stock plunges 70% after ADHD drug candidate misses primary endpoint
March 21, 2022 at 11:02 AM EDT
The company suffered a setback with its proprietary abuse-deterrent formulation of dextroamphetamine to treat ADHD.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|